You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指升破21,400 藥明生物(02269.HK)急漲一成
本港最新零售銷售額及PMI強勁。港股午後升幅進一步擴大,科指及工商分類指數升3.1%及2.8%,帶動恆指高見21,441,現報21,429,回升347點或1.6%,成交額1,004億元。 藍籌股以藥明生物(02269.HK)升幅最大,股價升破50天線(58.6元),最高見62.95元,現報62.65元,急漲一成。此外,藥明康德(02359.HK)高見101.1元,現報99.7元,回升9.3%。藥明生物指,旗下江蘇無錫市全新生物製劑五廠(DP5)已正式投入GMP生產,為集團於全球範圍內投產第九個生物製劑廠。DP5應用了先進的隔離器灌裝生產線,速度最快可達每分鐘400支,年產能高達1,700萬支。 金斯瑞生物科技(01548.HK)附屬傳奇生物科技(LEGN.US)公布,美國食品和藥物管理局(FDA)已批准其新藥臨床試驗(IND)申請,以評估在美國進行LB1908的I期臨床試驗。金斯瑞高見25.1元,現報24.7元,急漲近11%。 信達生物(01801.HK)公布旗下自主研發CAR-T細胞治療產品的注射液新藥上市申請已獲國家藥監局正式受理。該股高見26.35元,現報25.65元,升5.6%。 康希諾生物(06185.HK)高見78.7元,現報77.9元,升5.2%;康希諾(688185.SH)也漲逾半成曾高見183元人民幣。 聯邦制藥(03933.HK)及三生製藥(01530.HK)升3.5%左右,分別報3.7元及6.01元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account